Abstract 228P
Background
Cabozantinib, a novel TKI is an oral multitargeted inhibitor of VEGFR, MET and AXL kinases. The CABOSUN trial established the superiority of cabozantinib over sunitinib in newly diagnosed renal cell carcinoma (RCC) of intermediate or poor risk. Currently it is used as a single agent (intermediate risk) or in combination with nivolumab (intermediate and poor risk). However, data is lacking with respect to the real-world use patterns of cabozantinib.
Methods
In this study, we explored the use of single agent cabozantinib in advanced RCC in terms of dosing, effectiveness, tolerability, and toxicity profiles. This was a single center retrospective observational study from All India Institute of Medical Sciences, New Delhi, India. Data was collected retrospectively from prospectively maintained database. All eligible patients were aged 18 years or older, had measurable lesions, available case records, received at least 2 months of the drug and were evaluable for response.
Results
In total, 70 patients were identified with a median age of 53 years (interquartile, 47-65 years). Majority were males (81.4%). The different histologies were (clear cell 77.1%, papillary 11.4%, and translocation related 5.7%). 54.3% had prior nephrectomy. Majority had an IMDC score as intermediate (61.4%), followed by favorable (22.9%). Most common site of metastases was lung (60%) followed by bone (32.9%). Cabozantinib was started as the first line TKI in 60% (42/70), as 2nd line in 74.2% (23/31). Starting dose was 60mg in 27%, and 40mg in 73%. Dose reductions of cabozantinib were seen in 40.7% in 1st line, and 58.2% in 2nd line. Re escalation was done in 24.2%. Most common reason for dose reduction was diarrhea (64.7%). 35.7% had a partial response and 2.9% had a CR. ORR for overall population was 39.1%. Overall median PFS was 7.2 months. Most common adverse events were diarrhea in 42.7%, Hand-Foot skin reaction in 27.6%, mucositis in 17.8% and hepatotoxicity in 5.1%.
Conclusions
This study showed the practical dosing strategies and modifications of cabozantinib in the real world setting and how it differed from actual literature. We hope this study would help oncologists make better informed decisions while prescribing cabozantinib in advanced RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract